The CFO Mr. O'Toole made the statement in the webinar. He may have also said it in the Q call.
Reread the article, it compares advantages and disadvantages of each as stand alone allograft skin substitutes for the standard of care allograft which is cadaver skin. Guess I need to dig up Dr. Carter's webcast.
The CFO Mr. O'Toole made the statement in the webinar. He may...
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.99 |
Change
-0.070(2.29%) |
Mkt cap ! $210.5M | |||
| Open | High | Low | Value | Volume |
| $3.00 | $3.05 | $2.98 | $259.6K | 86.11K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 4898 | $2.98 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.02 | 3305 | 1 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| AVH (ASX) Chart |